Table 3A.
Infections (Severity grades 3–5*)
| N evaluable | Patients with Infections N (%) | |
|---|---|---|
| 1st 4 weeks | ||
| Bacterial | 24 | 16 (67%) |
| Gram negative | 1 | |
| Gram positive | 13 | |
| C. difficile | 2 | |
| Viral | 8 (33%) | |
| Polyoma | 3 | |
| HSV | 4 | |
| CMV | 1 | |
| Fungal | 2 (8%) | |
| Candida | 2 | |
| 5–8 weeks | ||
| Bacterial | 20 | 5 (25%) |
| Gram negative | 1 | |
| Gram positive | 4 | |
| Viral | 6 (30%) | |
| HSV | 1 | |
| CMV | 3 | |
| EBV | 1 | |
| Adenovirus | 1 | |
| Fungal | 0 | |
| 9–12 weeks | ||
| Bacterial | 20 | 6 (30%) |
| Gram negative | 1 | |
| Gram positive | 5 | |
| Viral | 5 (25%) | |
| HSV | 0 | |
| CMV | 4 | |
| EBV | 0 | |
| Adenovirus | 1 | |
| HHV-6 | 1 | |
| Fungal | 2 (10%) | |
| Candida | 2 | |
| 13–24 weeks | ||
| Bacterial | 16 | 4 (25%) |
| Gram negative | 0 | |
| Gram positive | 4 | |
| Viral | 3 (19%) | |
| HSV | 0 | |
| CMV | 2 | |
| EBV | 0 | |
| Adenovirus | 0 | |
| HHV-6 | 1 | |
| Fungal | 1 (6%) | |
| Yeast, nos | 1 | |
*
Grade 3 (requiring parenteral antimicrobial therapy; Grade 4 (life-threatening) and Grade 5 (fatal) infections reported over time.